Combination of lisinopril and nifedipine GITS increases blood pressure control compared with single drugs in essential hypertensive patients

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 4, 2003, Pages 579-585

  Taddei, Stefano ^a   Omboni, Stefano ^b   Ghiadoni, Lorenzo ^a   Caiazza, Alberto ^c   Fogari, Roberto ^d   Innocenti, Pierfranco ^e   Porcellati, Carlo ^f   Giovannetti, Roberto ^g   Corradi, Luca ^h   Mancia, Giuseppe ⁱ   Salvetti, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c Ospedale di Fidenza   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e Ospedale di Carrara   (Italy)

^f Osp Gen Regionale Raffaello S   (Italy)

^g Ospedale di Pescia   (Italy)

^h Presidio Ospedaliero ^*  (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiotensin; Blood pressure variability; Calcium antagonists; Converting enzyme inhibitors; Hypertension; Trough to peak ratio

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; NIFEDIPINE; NIFEDIPINE GITS; PLACEBO;

ADULT; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; NIFEDIPINE; STATISTICS, NONPARAMETRIC;

EID: 0037379857     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200304000-00010     Document Type: Article

References (31)

1. Stokes J, Kannel WB, Wolf PA, et al. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old. Circulation. 1987; 75(suppl V):65-73.
2. Guidelines Sub-Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension. J Hypertens. 1993;11:905-18.
3. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The sixth report. Arch Intern Med. 1997; 157: 2413-46.
4. Salvetti A, Caiazza A, Ghisoni F, et al. The dose-response curve of lisinopril in essential hypertensives: a cross-over multicenter study. In: Mac Gregor GA, Sever PS, eds. Current Advances in ACE Inhibition 2. London: Churchill-Livingstone; 1991:161-4.
5. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med. 1994;154:1430-1.
6. Fenichel RR, Lipicky RJ. Combination therapy as first-line pharmacotherapy. Arch Intern Med. 1994;154:1429-30.
7. Guazzi MD, De Cesare N, Galli C, et al. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation. 1984;70:279-84.
8. Menard J, Bellet M. Calcium antagonists-ACE inhibitors combination therapy: objectives and methodology of clinical development. J Cardiovasc Pharmacol. 1993;21(Suppl 2):S49-54.
9. Trazzi S, Mutti E, Frattola A, et al. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens. 1991;9:115-9.
10. Conway J, Coats A. Value of ambulatory blood pressure monitoring in clinical pharmacology. J Hypertens. 1989;7(suppl 3):S29-32.
11. Parati G, Pomidossi G, Alabini F, et al. Relationship of 24-h blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens. 1987;5:93-9.
12. Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-h blood pressure variability. J Hypertens. 1993;11:1133-7.
13. Palatini P, Penzo M, Racioppa A, et al. Clinical relevance of night-time blood pressure and of day-time blood pressure variability. Arch Intern Med. 1992;152:1856-60.
14. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension. 1993;21:510-22.
15. Parati G, Ulian L, Santucciu O, et al. Blood pressure variability, cardiovascular risk and antihypertensive treatment. J Hypertens. 1995; 13 (suppl 4):827-934.
16. Parati G, Omboni S, Rizzoni D, et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment of hypertension. J Hypertens. 1998;16:1685-91.
17. Omboni S, Fogari R, Palatini P, et al., on behalf of the SAMPLE Study Group. Reproducibility and clinical value of the through-to-peak ratio of the antihypertensive effect: evidence from the Sample Study. Hypertension. 1998;32:52-8.
18. Lipickky RJ. Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens. 1994;12(suppl 8):S17-19.
19. Rizzoni D, Muiesan ML, Salvetti M, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickening during antihypertensive treatment. J Hypertens. 2001;19: 703-11.
20. Zanchetti A, on behalf of the Italian nifedipine GITS Study Group. Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. J Hypertens. 1994;12(suppl 8):SS97-106.
21. Salvetti A, Virdis A, Taddei S, et al. Trough to peak ratio of nifedipine GITS and nifedipine retard in essential hypertensive patients: an Italian multicenter study. J Hypertens. 1996;14:661-7.
22. Groppelli A, Omboni S, Parati G, et al. Evaluation of noninvasive blood pressure monitoring device Spacelabs 90202 and 90207 versus resting and ambulatory 24-h intra-arterial blood pressure. Hypertension. 1992;20:227-32.
23. Omboni S, Parati G, Zanchetti A, et al. Calculation of trough-to-peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens. 1995;13:1105-12.
24. Zanchetti A, Hansson L, Dahlof B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001;19:1149-59.
25. Menard J, Chatellier G, Day M, et al. Self-measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio. J Hypertens. 1994;12:S21-5.
26. Casale PN, Devereux RB, Milner M. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-8.
27. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-6.
28. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of changes in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-6.
29. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990;81:528-36.
30. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
31. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-62.